BWXT Names Vittorio Puppo President of Medical Business
August 06 2024 - 6:45AM
Business Wire
BWX Technologies, Inc. (NYSE: BWXT) has appointed Vittorio Puppo
as president of BWXT Medical Ltd., effective August 12, 2024. In
his new role, Puppo will focus on advancing the business’ mission
to deliver high-quality nuclear medical products and solutions that
improve patient outcomes worldwide.
Puppo brings a wealth of experience to BWXT Medical, with over
30 years of experience in the areas of imaging, nuclear medicine,
radiation therapy and biotech, in both Europe and North America. In
his most recent roles, he served as chief operating officer of
Radiopharm Theranostics and held various positions with Bracco.
These include chief marketing and strategy officer of Bracco
Imaging, president and chief executive officer of Bracco
Diagnostics Inc., interim head of Corporate Business Development
and global head of Injectors Business Unit. Prior to Bracco, Puppo
held various senior level positions with Accuray, Covidien (now
part of Medtronic) and Amersham (now part of GE Healthcare).
“Vittorio’s extensive experience, strategic insight and
commitment to the medical manufacturing industry make him an ideal
fit to lead our medical business into its next phase of growth and
innovation,” said John MacQuarrie, president of BWXT commercial
operations. “We’re confident that, under his leadership, BWXT
Medical will continue to thrive and deliver increasing value to our
customers and collaborators.”
“I am honored to join BWXT Medical and lead such a talented team
dedicated to making a positive impact in the healthcare industry,”
said Puppo. “I look forward to building on the company’s strong
foundation and driving forward its vision of innovation, quality
and customer-centricity. Together, we will continue to develop
cutting-edge medical solutions that address the evolving needs of
our customers, healthcare providers and their patients.”
Puppo holds a degree in finance and economics and a Master of
Business Administration from the SDA Bocconi School of Management
in Italy. He held the position of vice president of the European
Association of Imaging Producers and Equipment Suppliers between
2004 and 2008, and has been a board member of the Medical Imaging
and Technology Alliance since 2021.
Puppo succeeds Jonathan Cirtain, whose expertise and dedication
have been instrumental to BWXT Medical’s progress to-date. Cirtain
will transition back full-time into his role as BWXT’s chief
development officer, continuing to support BWXT Medical, along with
the company’s broader innovation goals.
About BWXT Medical Ltd.
BWXT Medical Ltd. manufactures custom radiopharmaceuticals,
radiotherapies and medical isotopes in an 80,000-square-foot cGMP
manufacturing facility in Ottawa and at the state-of-the-art
commercial cyclotron facility within TRIUMF, Canada’s particle
acceleration centre. BWXT Medical Ltd. is a subsidiary of BWX
Technologies, Inc. (NYSE: BWXT). BWXT is a manufacturing and
engineering innovator that provides safe and effective nuclear
solutions for global security, clean energy, environmental
restoration, nuclear medicine and space exploration. Learn more at
www.bwxtmedical.com and follow us on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240806549933/en/
Media Contact Monifa Miller Senior Director, Corporate
Affairs Commercial Operations 519.242.8071 mamiller@bwxt.com
Investor Contact Chase Jacobson Vice President, Investor
Relations 980.365.4300 investors@bwxt.com
BWX Technologies (NYSE:BWXT)
Historical Stock Chart
From Aug 2024 to Sep 2024
BWX Technologies (NYSE:BWXT)
Historical Stock Chart
From Sep 2023 to Sep 2024